Comparative Pharmacology
Head-to-head clinical analysis: AQUAPHYLLIN versus THEOLIXIR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AQUAPHYLLIN versus THEOLIXIR.
AQUAPHYLLIN vs THEOLIXIR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phosphodiesterase-3 (PDE3) inhibitor with additional adenosine receptor antagonism and weak inhibition of phosphodiesterase-4 (PDE4). Increases intracellular cAMP and cGMP, leading to bronchodilation and anti-inflammatory effects.
Theophylline is a xanthine derivative that acts as a competitive nonselective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, and as an antagonist at adenosine receptors (A1 and A2 subtypes), leading to bronchodilation, anti-inflammatory effects, and stimulation of respiratory drive.
300 mg orally every 6 hours as needed for acute asthma exacerbation; for chronic maintenance, 300 mg orally every 8 hours.
Oral: 200-400 mg every 6 hours (maximum 1600 mg/day) as sustained-release tablets or liquid. Inhalation: Not applicable.
None Documented
None Documented
Terminal elimination half-life: 3-5 hours in healthy adults; prolonged to 8-12 hours in neonates and up to 30 hours in cirrhosis.
Terminal elimination half-life is 3–5 hours in adults (nonsmokers), but prolonged to 6–8 hours in neonates, elderly, and patients with hepatic cirrhosis or heart failure. Smoking (tobacco or marijuana) reduces half-life to 1–2 hours due to enzyme induction.
Renal: 90-95% unchanged; biliary/fecal: <5%.
Renal excretion of unchanged drug accounts for approximately 10% of elimination; the remainder is hepatically metabolized, with 80% excreted in urine as metabolites (1-methyluric acid and 3-methylxanthine) and less than 10% in feces.
Category C
Category C
Bronchodilator
Bronchodilator